Generic Medicine Info
Indications and Dosage
Susceptible infections
Adult: As sodium: 1-2 g daily in 2 divided doses by injection/infusion.
Infectious mononucleosis, lymphatic leukaemia, HIV infection; hypersensitivity to penicillins.
Special Precautions
Very high doses in poor renal function (risk of neurotoxicity) or heart failure. Avoid contact, skin sensitization may occur. Monitor serum K concentration, renal and haematological status. Spirochete infections particularly syphilis; suprainfection with penicillin-resistant organisms with prolonged use; avoid intrathecal route. Discontinue in case of skin rash.
Adverse Reactions
Hypersensitivity reactions including uticaria; fever; joint pains; rashes; angioedema; serum sickness-like reactions; haemolytic anaemia; interstitial nephritis; neutropaenia; thrombocytopaenia; CNS toxicity including convulsions; diarrhoea; nausea; vomiting.
Potentially Fatal: Pseudomembranous colitis.
Drug Interactions
Prolonged 1/2 life when used with probenecid. Bacteriostatic drugs eg chloramphenicol, tetracyclines; other antibacterials; anticoagulants.
Lab Interference
May interfere with diagnostic tests for urinary glucose using copper sulfate, direct Coomb's test, and test for urinary or serum proteins. May interfere with diagnostic tests that use bacteria.
Mechanism of Action: Cefpiramide is active against P. aeruginosa, but possibly less active against Enterobacteriaceae. It is also active against staphylococci and streptococci and marginally active against enterococci in vitro. It inhibits final cross-linking stage of peptidoglycan production through binding and inactivation of transpeptidases on the inner surface of the bacterial cell membrane thus inhibiting bacterial cell wall synthesis.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Cefpiramide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in